Skip to main content

Table 1 Demographics of gastroesophageal junction cancer patients

From: The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study

Ā 

Patients without MLND

Group A

(Nā€‰=ā€‰261)

Patients with MLND

Group B

(Nā€‰=ā€‰29)

Value

Age

60.6ā€‰Ā±ā€‰12.1

61.4ā€‰Ā±ā€‰11.0

0.751

Sex

Ā Ā 

0.641

ā€ƒMale

200 (76.6%)

24 (82.8%)

Ā 

ā€ƒFemale

61 (23.4%)

5 (17.2%)

Ā 

BMI*

23.6ā€‰Ā±ā€‰3.5

23.0ā€‰Ā±ā€‰3.5

0.492

ASA score**

Ā Ā 

0.809

ā€ƒ0

82 (31.4%)

10 (34.4%)

Ā 

ā€ƒ1

162 (62.0%)

17 (58.6%)

Ā 

ā€ƒ2 or more

17 (6.5%)

2 (6.8%)

Ā 

Siewert Type

Ā Ā 

0.019

ā€ƒType II

103 (39.5%)

18 (62.1%)

Ā 

ā€ƒType III

158 (60.5%)

11 (37.9%)

Ā 

ā€ƒTumor size

4.4ā€‰Ā±ā€‰2.5

5.7ā€‰Ā±ā€‰2.9

0.025

Surgical procedure

Ā Ā 

<ā€‰0.001

ā€ƒTotal gastrectomy

238 (91.2%)

16 (55.2%)

Ā 

ā€ƒProximal gastrectomy

23 (8.8%)

1 (3.4%)

Ā 

ā€ƒEsophagectomy (Ivor Lewis)

0 (0%)

12 (41.4%)

Ā 

Splenectomy

Ā Ā 

1.000

ā€ƒYes

17 (6.5%)

1 (3.4%)

Ā 

ā€ƒNo

244 (93.5%)

28 (96.6%)

Ā 

Histopathological type

Ā Ā 

0.064

ā€ƒDifferentiated

103 (39.8%)

16 (56.2%)

Ā 

ā€ƒUndifferentiated

142 (54.8%)

13 (44.8%)

Ā 

ā€ƒOthers

14 (5.4%)

0 (0%)

Ā 

Lauren classification

Ā Ā 

0.006

ā€ƒIntestinal

144 (55.2%)

12 (41.4%)

Ā 

ā€ƒDiffuse

79 (30.3%)

8 (27.6%)

Ā 

ā€ƒMixed

24 (9.2%)

2 (6.9%)

Ā 

ā€ƒUnknown

14 (5.4%)

7 (24.1%)

Ā 

ā€ƒProximal margin

1.9ā€‰Ā±ā€‰1.1

4.6ā€‰Ā±ā€‰4.9

<ā€‰0.001

Extent of Abdominal

Ā Ā 

<ā€‰0.001

ā€ƒLN dissection

Ā Ā Ā 

ā€ƒD1+

36 (13.8%)

15 (51.7%)

Ā 

ā€ƒD2 or more

225 (86.2%)

14 (48.3%)

Ā 

ā€ƒHarvested LNs

42.4ā€‰Ā±ā€‰16.7

43.1ā€‰Ā±ā€‰14.6

0.827

ā€ƒMetastatic LNs

3.0ā€‰Ā±ā€‰6.4

5.8ā€‰Ā±ā€‰6.7

0.043

T category

Ā Ā 

0.035

ā€ƒpT1

107 (41.0%)

6 (20.7%)

Ā 

ā€ƒpT2

45 (17.2%)

5 (17.2%)

Ā 

ā€ƒpT3

70 (26.8%)

12 (41.4%)

Ā 

ā€ƒpT4

39 (14.9%)

6 (20.7%)

Ā 

pN category

Ā Ā 

0.006

ā€ƒpN0

158 (60.5%)

6 (20.7%)

Ā 

ā€ƒpN1

34 (13.0%)

11 (37.9%)

Ā 

ā€ƒpN2

26 (10.0%)

5 (17.2%)

Ā 

ā€ƒpN3

43 (16.5%)

7 (24.1%)

Ā 

Cytology

Ā Ā 

0.027

ā€ƒnegative

260 (99.6%)

27 (93.1%)

Ā 

ā€ƒPositive

1 (0.4%)

2 (6.9%)

Ā 

Stage***

Ā Ā 

<ā€‰0.001

ā€ƒStage I

147 (56.3%)

6 (20.7%)

Ā 

ā€ƒStage II

54 (20.7%)

12 (41.4%)

Ā 

ā€ƒStage III

57 (21.8%)

8 (27.6%)

Ā 

ā€ƒStage IV

3 (1.1%)

3 (10.3%)

Ā 

Adjuvant ChemoTx

87 (33.3%)

20 (68.9%)

<ā€‰0.001

  1. * MLND mediastinal lymph node dissection
  2. *BMI body mass index (kg/m2)
  3. **ASA American Society of Anesthesiologists
  4. *** AJCC 7th edition: Esophagus and Esophagogastric Junction